No annual revenue total was found in Edgewise Therapeutics, Inc.'s SEC filings.
Edgewise Therapeutics, Inc. (EWTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$144.1 million. As of Sep 30, 2026 it held $1.7 billion in cash and investments and $3.4 million in total debt.
Revenue
—
Net income (TTM)
$1.01B
+742.1% vs year-ago TTM
Operating cash flow (TTM)
$-201.90M
-52.7% vs year-ago TTM
Free cash flow (TTM)
$-202.28M
EPS (TTM)
$8.69
+653.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
107.27M
+12.7% vs prior year
Net cash
$1.74B
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EWTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1710072
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M |
| Diluted EPS | -$1.63 | -$1.45 | -$1.57 | -$1.26 | -$1.14 |
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
| Stockholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M |
| Cash and investments | $530.1M | $470.2M | $318.4M | $351.9M | $280.8M |
| Total debt | $4.0M | $4.7M | $5.4M | $4.4M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K/A | Amended current report | Jul 16, 2026 | Jul 10, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
Jul 13, 2026 | Jul 10, 2026 |
All 421 Edgewise Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.